Publications by authors named "Vissal-David Kheav"

Article Synopsis
  • The study assesses the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab for kidney transplant candidates with high panel reactive antibodies.
  • In the trial, 23 patients were involved across two phases, with notable mild infusion-related adverse events but no serious complications.
  • Results showed significant, temporary reductions in anti-HLA antibodies at 3 months, but most immune markers returned to baseline levels after 12 months, indicating less than 40% of patients had a lasting positive response.
View Article and Find Full Text PDF
Article Synopsis
  • Systemic sclerosis is a severe autoimmune disease, and mesenchymal stromal cells (MSCs) show potential for treatment due to their immunomodulatory and antifibrotic properties, although their safety in patients has not been confirmed.
  • A phase 1/2 study at Saint-Louis Hospital in Paris aimed to determine the safety and feasibility of injecting allogeneic MSCs from family donors into patients with severe diffuse systemic sclerosis.
  • The study involved 20 eligible patients, assessing immediate infusion tolerance and monitoring serious adverse events over a 24-month follow-up period.
View Article and Find Full Text PDF

Background: Sensitized patients, i.e. recipients with preformed donor-specific HLA antibodies (pfDSA), are at high-risk of developing antibody-mediated rejections (AMR) and dying after heart transplantation (HTx).

View Article and Find Full Text PDF

Allele specific antibody response against the polymorphic system of HLA is the allogeneic response marker determining the immunological risk for graft acceptance before and after organ transplantation and therefore routinely studied during the patient's workup. Experimentally, bead bound antigen- antibody reactions are detected using a special multicolor flow cytometer (Luminex). Routinely for each sample, antibody responses against 96 different HLA antigen groups are measured simultaneously and a 96-dimensional immune response vector is created.

View Article and Find Full Text PDF

Pre-transplant serum screening of anti-HLA antibodies is recommended for solid organ transplantations. Many laboratories use the less expensive bead-based screening assay as the main technique and, if positive, turn to single-antigen beads (SAB). We studied the correlations between these two immunoassays.

View Article and Find Full Text PDF

After heart transplant, adding everolimus (EVL) to standard immunosuppressive regimen mostly relies on converting calcineurin inhibitors (CNIs) into EVL. The aim of this study was to describe the effects of combining low-dose EVL and CNIs in maintenance immunosuppression regimen (quadritherapy) and compare it with standard tritherapy associating standard-dose CNIs, mycophenolate mofetil, and corticosteroids. In the 3-year registry cohort of heart transplanted patients, those who received quadritherapy were compared with those who received tritherapy.

View Article and Find Full Text PDF

A major hurdle to improving clinical care in the field of kidney transplantation is the lack of biomarkers of the response to antibody-mediated rejection (ABMR) treatment. To discover these we investigated the value of complement-binding donor-specific anti-HLA antibodies (DSAs) for evaluating the response to treatment. The study encompassed a prospective cohort of 139 kidney recipients with ABMR receiving the standard of care treatment, including plasma exchange, intravenous immunoglobulin and rituximab.

View Article and Find Full Text PDF

Natural killer cells are the first lymphocyte subset to reconstitute, and play a major role in early immunity after allogeneic hematopoietic stem cell transplantation. Cells expressing the activating receptor NKG2C seem crucial in the resolution of cytomegalovirus episodes, even in the absence of T cells. We prospectively investigated natural killer-cell reconstitution in a cohort of 439 adult recipients who underwent non-T-cell-depleted allogeneic hematopoietic stem cell transplantation between 2005 and 2012.

View Article and Find Full Text PDF